121 related articles for article (PubMed ID: 38235615)
1. A partial epithelial-mesenchymal transition signature for highly aggressive colorectal cancer cells that survive under nutrient restriction.
Pastorino GA; Sheraj I; Huebner K; Ferrero G; Kunze P; Hartmann A; Hampel C; Husnugil HH; Maiuthed A; Gebhart F; Schlattmann F; Gulec Taskiran AE; Oral G; Palmisano R; Pardini B; Naccarati A; Erlenbach-Wuensch K; Banerjee S; Schneider-Stock R
J Pathol; 2024 Mar; 262(3):347-361. PubMed ID: 38235615
[TBL] [Abstract][Full Text] [Related]
2. Epithelial-to-mesenchymal transition signature assessment in colorectal cancer quantifies tumour stromal content rather than true transition.
McCorry AM; Loughrey MB; Longley DB; Lawler M; Dunne PD
J Pathol; 2018 Dec; 246(4):422-426. PubMed ID: 30105762
[TBL] [Abstract][Full Text] [Related]
3. GRHL2 inhibits colorectal cancer progression and metastasis via oppressing epithelial-mesenchymal transition.
Yang Z; Wu D; Chen Y; Min Z; Quan Y
Cancer Biol Ther; 2019; 20(9):1195-1205. PubMed ID: 31063022
[TBL] [Abstract][Full Text] [Related]
4. Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression.
Ji Q; Liu X; Han Z; Zhou L; Sui H; Yan L; Jiang H; Ren J; Cai J; Li Q
BMC Cancer; 2015 Mar; 15():97. PubMed ID: 25884904
[TBL] [Abstract][Full Text] [Related]
5. Cadherin-12 enhances proliferation in colorectal cancer cells and increases progression by promoting EMT.
Ma J; Zhao J; Lu J; Wang P; Feng H; Zong Y; Ou B; Zheng M; Lu A
Tumour Biol; 2016 Jul; 37(7):9077-88. PubMed ID: 26762412
[TBL] [Abstract][Full Text] [Related]
6. N-cadherin, a novel prognostic biomarker, drives malignant progression of colorectal cancer.
Yan X; Yan L; Liu S; Shan Z; Tian Y; Jin Z
Mol Med Rep; 2015 Aug; 12(2):2999-3006. PubMed ID: 25936636
[TBL] [Abstract][Full Text] [Related]
7. Elevated soluble E-cadherin during the epithelial-mesenchymal transition process and as a diagnostic marker in colorectal cancer.
Zhu S; Zhao G; Zhao X; Zhan X; Cai M; Geng C; Pu Q; Zhao Q; Fu Q; Huang C; Wang Q
Gene; 2020 Sep; 754():144899. PubMed ID: 32544494
[TBL] [Abstract][Full Text] [Related]
8. CDX2 as a Predictive Biomarker Involved in Immunotherapy Response Suppresses Metastasis through EMT in Colorectal Cancer.
Wang YS; Kou Y; Zhu RT; Han BW; Li CH; Wang HJ; Wu HB; Xia TM; Che XM
Dis Markers; 2022; 2022():9025668. PubMed ID: 36277982
[TBL] [Abstract][Full Text] [Related]
9. Silencing of E-cadherin expression leads to increased chemosensitivity to irinotecan and oxaliplatin in colorectal cancer cell lines.
Skarkova V; Skarka A; Manethova M; Stefanidi AA; Rudolf E
Hum Exp Toxicol; 2021 Dec; 40(12):2063-2073. PubMed ID: 34075792
[TBL] [Abstract][Full Text] [Related]
10. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines.
Yang AD; Fan F; Camp ER; van Buren G; Liu W; Somcio R; Gray MJ; Cheng H; Hoff PM; Ellis LM
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4147-53. PubMed ID: 16857785
[TBL] [Abstract][Full Text] [Related]
11. A Gene Signature Derived from the Loss of CDKN1A (p21) Is Associated with CMS4 Colorectal Cancer.
Bueno-Fortes S; Muenzner JK; Berral-Gonzalez A; Hampel C; Lindner P; Berninger A; Huebner K; Kunze P; Bäuerle T; Erlenbach-Wuensch K; Sánchez-Santos JM; Hartmann A; De Las Rivas J; Schneider-Stock R
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008299
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis.
Hur K; Toiyama Y; Takahashi M; Balaguer F; Nagasaka T; Koike J; Hemmi H; Koi M; Boland CR; Goel A
Gut; 2013 Sep; 62(9):1315-26. PubMed ID: 22735571
[TBL] [Abstract][Full Text] [Related]
13. High TrkB expression levels are associated with poor prognosis and EMT induction in colorectal cancer cells.
Fujikawa H; Tanaka K; Toiyama Y; Saigusa S; Inoue Y; Uchida K; Kusunoki M
J Gastroenterol; 2012 Jul; 47(7):775-84. PubMed ID: 22361863
[TBL] [Abstract][Full Text] [Related]
14. Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition.
Xiong H; Hong J; Du W; Lin YW; Ren LL; Wang YC; Su WY; Wang JL; Cui Y; Wang ZH; Fang JY
J Biol Chem; 2012 Feb; 287(8):5819-32. PubMed ID: 22205702
[TBL] [Abstract][Full Text] [Related]
15. An hTERT/ZEB1 complex directly regulates E-cadherin to promote epithelial-to-mesenchymal transition (EMT) in colorectal cancer.
Qin Y; Tang B; Hu CJ; Xiao YF; Xie R; Yong X; Wu YY; Dong H; Yang SM
Oncotarget; 2016 Jan; 7(1):351-61. PubMed ID: 26540342
[TBL] [Abstract][Full Text] [Related]
16. BMAL1 Knockdown Leans Epithelial-Mesenchymal Balance toward Epithelial Properties and Decreases the Chemoresistance of Colon Carcinoma Cells.
Zhang Y; Devocelle A; Desterke C; de Souza LEB; Hadadi É; Acloque H; Foudi A; Xiang Y; Ballesta A; Chang Y; Giron-Michel J
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065633
[TBL] [Abstract][Full Text] [Related]
17. SPP1, analyzed by bioinformatics methods, promotes the metastasis in colorectal cancer by activating EMT pathway.
Xu C; Sun L; Jiang C; Zhou H; Gu L; Liu Y; Xu Q
Biomed Pharmacother; 2017 Jul; 91():1167-1177. PubMed ID: 28531945
[TBL] [Abstract][Full Text] [Related]
18. Role of Epithelial to Mesenchymal Transition in Colorectal Cancer.
Lu J; Kornmann M; Traub B
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834263
[TBL] [Abstract][Full Text] [Related]
19. NUBPL, a novel metastasis-related gene, promotes colorectal carcinoma cell motility by inducing epithelial-mesenchymal transition.
Wang Y; Wu N; Sun D; Sun H; Tong D; Liu D; Pang B; Li S; Wei J; Dai J; Liu Y; Bai J; Geng J; Fu S; Jin Y
Cancer Sci; 2017 Jun; 108(6):1169-1176. PubMed ID: 28346728
[TBL] [Abstract][Full Text] [Related]
20. Unraveling the function of epithelial-mesenchymal transition (EMT) in colorectal cancer: Metastasis, therapy response, and revisiting molecular pathways.
Sabouni E; Nejad MM; Mojtabavi S; Khoshduz S; Mojtabavi M; Nadafzadeh N; Nikpanjeh N; Mirzaei S; Hashemi M; Aref AR; Khorrami R; Nabavi N; Ertas YN; Salimimoghadam S; Zandieh MA; Rahmanian P; Taheriazam A; Hushmandi K
Biomed Pharmacother; 2023 Apr; 160():114395. PubMed ID: 36804124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
